To evaluate the effect of KAT2B on glioma, the glioma cell lines, including U251 and LN229 cells, were treated with KAT2B overexpressing plasmids or KAT2B shRNAs, and the effectiveness of KAT2B overexpression and depletion was validated in the cells (Figures 1(b)–1(e)). The gene discussed is KAT2B; the disease is central nervous system cancer.